Egyptian study reveals hidden breast cancer subtype

NCT ID NCT06188494

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study reviewed medical records of 405 people in Egypt with advanced HER2-negative breast cancer to find out how many actually have a subtype called HER2-low. Researchers looked at past test results to estimate the prevalence. The goal is to better understand who might be eligible for newer treatments targeting HER2-low cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better identify patients who might benefit from newer targeted therapies for HER2-low breast cancer.
What could go wrong: This is an observational study that only looks back at existing data, so it cannot prove any treatment works. The results may not apply to other populations or testing methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Research Site

Alexandria, Egypt
Research Site

Asyut, Egypt
Research Site

Cairo, Egypt
Research Site

Gharbia, Egypt
Research Site

Giza, Egypt
Research Site

Luxor, Egypt
Research Site

Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.